Syngene Internation.
Ticker > Company >

Syngene Internation. share price

Syngene International Ltd.

NSE: SYNGENE BSE: 539268 SECTOR: Business Support  150k   527   99

861.95
+2.55 (0.30%)
BSE: 14 Nov 04:01 PM

Price Summary

Today's High

₹ 868.8

Today's Low

₹ 857.75

52 Week High

₹ 945.75

52 Week Low

₹ 608

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 34696.68 Cr.

Enterprise Value

₹ 34310.18 Cr.

No. of Shares

40.25 Cr.

P/E

75.41

P/B

8.03

Face Value

₹ 10

Div. Yield

0.15 %

Book Value (TTM)

₹  107.28

CASH

₹ 528.2 Cr.

DEBT

₹ 141.7 Cr.

Promoter Holding

54.72 %

EPS (TTM)

₹  11.43

Sales Growth

0.3%

ROE

12.07 %

ROCE

13.76%

Profit Growth

-1.37 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 22 Indices.

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
41153.9
  261.450000000004 (0.639360077471518%)

NMID150Q50

NIFTY Midcap150 Quality 50
23822.8
  -12.25 (-0.0513948995282121%)

NIFTY500

Nifty 500
21963.1
  48.1499999999978 (0.219713026951918%)

NIFTYMIDCAP150

Nifty Midcap 150
20105.25
  94.5 (0.472246167684864%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
18966.05
  110.450000000001 (0.585767623411626%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15341.7
  53.7000000000007 (0.351255886970181%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15279.7
  41.9500000000007 (0.275303112336145%)

NIFTYHEALTH

Nifty Healthcare Index
13865.6
  -46.7999999999993 (-0.336390558063304%)

NIFTYTOTALMCAP

NIFTY Total Market
12381.9
  30.6499999999996 (0.248153020949293%)

NFT500EQUAL

Nifty 500 Equal Weight
13697.46
  65.9199999999983 (0.48358439325269%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

SMLCAP

Bse SmallCap
52381.98
  429.190000000002 (0.826115402079464%)

BSE HC

Bse Healthcare
42509.23
  73.9400000000023 (0.174241769055894%)

BSE500

Bse 500
34600.01
  66.4300000000003 (0.192363490839931%)

MID150

Bse 150 MidCap Index
15246.06
  68.3099999999995 (0.450066709492503%)

200EQW

BSE 200 Equal Weight
12427.09
  32.1700000000001 (0.259541812290842%)

MSL400

Bse 400 MidSmallCap Index
11626.85
  61.2100000000009 (0.529240059348224%)

BSE200

Bse 200
10803.52
  14.9700000000012 (0.138758220520852%)

LMI250

Bse 250 LargeMidCap Index
10241.79
  14.2700000000004 (0.139525515471983%)

SMLSEL

Bse SmallCap Select Index
7728.24
  60.6999999999998 (0.791648951293378%)

ALLCAP

Bse Allcap
10471.31
  71.0699999999997 (0.683349615008888%)

S&P MIDSMLCAP

Bse MidSmallCap
12902.03
  80.3299999999999 (0.626515984619824%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year0.3%
3 Year13.7%
5 Year11.9%

Profit Growth

1 Year-1.37%
3 Year4.94%
5 Year7.12%

ROE%

1 Year12.07%
3 Year13.1%
5 Year15.21%

ROCE %

1 Year13.76%
3 Year14.19%
5 Year15.5%

Debt/Equity

0.0339

Price to Cash Flow

37.99

Interest Cover Ratio

19.8915

CFO/PAT (5 Yr. Avg.)

1.72650686525483

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 54.72 0.00
Jun 2024 54.72 0.00
Mar 2024 54.79 0.00
Dec 2023 54.79 0.00
Sep 2023 54.79 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 433.6 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 19.8915.
  • The Company has been maintaining an effective average operating margins of 28.9496856856403% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -1574.4712 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.72650686525483.
  • The company has a high promoter holding of 54.72%.

 Limitations

  • The company has shown a poor profit growth of 4.93756106942773% for the Past 3 years.
  • The company has shown a poor revenue growth of 13.6956789632428% for the Past 3 years.
  • The company is trading at a high PE of 75.41.
  • The company is trading at a high EV/EBITDA of 36.7969.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 830.7 791.9 864.7 726.5 821.3
Total Expenditure 614.1 592.4 565.4 578.3 616.7
Operating Profit 216.6 199.5 299.3 148.2 204.6
Other Income 21 28.8 15.3 17.7 20.4
Interest 8.6 6.3 8.5 7.4 7
Depreciation 90.9 93.6 95.7 91.7 93.7
Exceptional Items -7.4 -3.7 0 32 0
Profit Before Tax 130.7 124.7 210.4 98.8 124.3
Tax 29.1 24.9 20.6 24.9 27.7
Profit After Tax 101.6 99.8 189.8 73.9 96.6
Adjusted EPS (Rs) 2.53 2.48 4.72 1.84 2.4

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 2011.9 2179.4 2601.4 3193.5 3203.1
Total Expenditure 1409.7 1528.1 1863.6 2260.9 2324.4
Operating Profit 602.2 651.3 737.8 932.6 878.7
Other Income 96.1 83.3 108.4 72.6 88
Interest 34.6 27.7 24.1 45.2 29.5
Depreciation 219.3 274.5 309.7 359.1 368.8
Exceptional Items 71.3 35 -30.7 0 -11.1
Profit Before Tax 515.7 467.4 481.7 600.9 557.3
Tax 104.2 63.7 87.9 127.9 90.8
Net Profit 411.5 403.7 393.8 473 466.5
Adjusted EPS (Rs.) 10.29 10.09 9.83 11.78 11.6

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 400 400 400.8 401.4 402
Total Reserves 1774.1 2418.3 2891.2 3217.5 3789.5
Borrowings 0 512.4 531.5 489 100
Other N/C liabilities 325.2 327.7 440.7 291.4 394
Current liabilities 1540 1130.4 1231.5 1157.2 1098.6
Total Liabilities 4039.3 4788.8 5495.7 5768.4 5784.1
Assets
Net Block 1983.7 2163.4 2354.3 2211.8 2276.8
Capital WIP 234.1 237.2 346.4 126.2 758.3
Intangible WIP 0 0 0 0 1.3
Investments 38.3 279 270.6 116.4 435
Loans & Advances 107.8 115.1 150.7 164.5 230.3
Other N/C Assets 64 193.1 170.1 794.2 230.6
Current Assets 1611.4 1801 2203.6 2355.3 1851.8
Total Assets 4039.3 4788.8 5495.7 5768.4 5784.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 515.7 467.4 481.7 600.9 557.3
Adjustment 223.2 278.6 381.3 375.3 289.2
Changes in Assets & Liabilities 44.9 34.8 -176.6 -4.1 165.3
Tax Paid -106.4 -82.8 -104.2 -133.7 -98.4
Operating Cash Flow 677.4 698 582.2 838.4 913.4
Investing Cash Flow -423.8 -628.9 -610.8 -685.1 -382.6
Financing Cash Flow -225.5 58 -31.3 -340.2 -536.3
Net Cash Flow 28.1 127.1 -59.9 -186.9 -5.5

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 54.79 54.79 54.79 54.72 54.72
biocon limited 54.52 54.52 54.52 54.45 54.45
biocon limited employee w... 0.26 0.26 0.26 0.26 0.26
kiran mazumdar shaw 0.01 0.01 0.01 0.01 0.01
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 45.21 45.21 45.21 45.28 45.28
government of singapore 2.94 2.94 2.94 2.94 2.94
government pension fund g... 2.10 2.19 2.22 1.97 1.92
icici prudential innovati... - - - - 5.20
kotak funds - india midca... 1.27 1.27 1.23 1.13 1.04
lici ulip-growth fund - - - - 1.73
mirae asset equity saving... - - - - 1.87
nippon life india trustee... - - - - 1.92
uti nifty midcap 150 qual... - - - - 1.72
icici prudential large & ... - - - 6.26 -
lici new endowment plus-g... - - - 1.22 -
mirae asset focused fund - - - 1.41 -
nippon life india trustee... - - - 1.54 -
uti-unit linked insurance... 1.46 1.46 - 1.83 -
icici prudential business... - - 5.97 - -
life insurance corporatio... - - 1.18 - -
mirae asset healthcare fu... 1.04 - 1.21 - -
uti-mid cap fund - - 1.81 - -
icici prudential pharma h... - 5.06 - - -
mirae asset nifty midcap ... - 1.16 - - -
icici prudential midcap f... 2.13 - - - -
invesco india arbitrage f... 1.10 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Syngene Internation. - Quaterly Results 23 Oct, 3:25 PM Syngene Internation. - Quaterly Results 23 Oct, 3:25 PM Syngene Internation. - Quaterly Results 23 Oct, 3:25 PM Syngene International informs about disclosure 1 Oct, 5:28 PM Syngene International informs about investor presentation 24 Jul, 5:28 PM Syngene International informs about outcome of board meeting 24 Jul, 4:23 PM Syngene Internation. - Quaterly Results 24 Jul, 3:04 PM Syngene Internation. - Quaterly Results 24 Jul, 3:04 PM Syngene Internation. - Quaterly Results 24 Jul, 3:04 PM Syngene International informs about disbursements 25 Jun, 2:17 PM Syngene Internation. - Quaterly Results 24 Apr, 7:46 PM Syngene Internation. - Quaterly Results 24 Apr, 7:46 PM Syngene International informs about disclosure 30 Mar, 11:13 AM Syngene International informs about analyst meet 21 Feb, 5:10 PM Syngene Internation. - Quaterly Results 25 Jan, 2:31 PM Syngene Internation. - Quaterly Results 25 Jan, 2:31 PM Syngene Internation. - Quaterly Results 25 Jan, 2:31 PM Syngene International informs about update 23 Dec, 11:53 AM Syngene International informs about analyst meet 14 Dec, 5:21 PM Syngene International submits intimation on analyst meeting 11 Dec, 5:17 PM Syngene International informs about analyst meet 6 Dec, 5:03 PM Syngene International concludes acquisition of biologics manufacturing facility 2 Dec, 4:08 PM Syngene International reports 14% rise in Q2 consolidated net profit 18 Oct, 11:50 AM Syngene Internation. - Quaterly Results 17 Oct, 6:43 PM Syngene Internation. - Quaterly Results 17 Oct, 6:43 PM Syngene Internation. - Quaterly Results 17 Oct, 6:43 PM Syngene International submits analyst meet intimation 21 Aug, 5:02 PM Syngene International informs about voting results and scrutinizer’s report 28 Jul, 9:58 AM Syngene Internation. - Quaterly Results 26 Jul, 3:26 PM Syngene Internation. - Quaterly Results 26 Jul, 3:26 PM Syngene Internation. - Quaterly Results 26 Jul, 3:26 PM Syngene International to acquire Unit 3 biologics manufacturing facility from Stelis Biopharma 5 Jul, 9:26 AM Syngene International submits analyst meet intimation 19 Jun, 5:00 PM Syngene International informs about analyst meet 6 Jun, 4:17 PM Syngene International submits analyst meet intimation 2 Jun, 4:57 PM Syngene International submits analyst meet intimation 24 May, 5:13 PM Syngene International informs about analyst meet 16 May, 1:38 PM Syngene International reports 21% rise in Q4 consolidated net profit 27 Apr, 1:01 PM Syngene Internation. - Quaterly Results 26 Apr, 6:54 PM Syngene Internation. - Quaterly Results 26 Apr, 6:54 PM Syngene Internation. - Quaterly Results 26 Apr, 6:54 PM Syngene International informs about board meeting 8 Apr, 12:21 PM Syngene International informs about newspaper publication 25 Mar, 2:43 PM Syngene International submits analyst meet intimation 3 Mar, 5:08 PM Syngene International submits analyst meet intimation 27 Feb, 4:51 PM Syngene International informs about analyst meet 21 Feb, 3:24 PM Syngene International informs about analyst meet 20 Feb, 12:41 PM Syngene International informs about cancellation of conference call 17 Feb, 9:56 AM Syngene International informs about investors meet 30 Jan, 12:18 PM Syngene International informs about analyst meet 27 Jan, 12:42 PM

Syngene Internation. Stock Price Analysis and Quick Research Report. Is Syngene Internation. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Syngene Internation. stock price today is Rs 861.6. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Syngene Internation. . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Syngene Internation. has a PE ratio of 75.3805774278215 which is high and comparatively overvalued .

  • Share Price: - The current share price of Syngene Internation. is Rs 861.6. One can use valuation calculators of ticker to know if Syngene Internation. share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Syngene Internation. has ROA of 8.0762 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Syngene Internation. has a Current ratio of 1.6856 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Syngene Internation. has a ROE of 12.0695 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Syngene Internation. has a Debt to Equity ratio of 0.0339 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Syngene Internation. has reported revenue growth of 0.3006 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Syngene Internation. for the current financial year is 27.4327994755081 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Syngene Internation. is Rs 1.25 and the yield is 0.145 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Syngene Internation. is Rs 11.43 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Syngene Internation. in Ticker for free. Also, one can get the intrinsic value of Syngene Internation. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Syngene Internation.

Syngene International Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Syngene International Ltd. is a leading contract research organization (CRO) in India, providing integrated drug discovery and development services to the global pharmaceutical industry.  We will provide a comprehensive analysis of Syngene International Ltd.'s stock performance and key financial indicators.

Syngene International Ltd. Share Price

Syngene International Ltd.'s share price has been consistently increasing over the years due to the company's strong financial performance and growth prospects. The company has a stable business model and a diverse range of clients, which provides investors with a sense of security and stability. Investors can use our pre-built screening tools to track Syngene International Ltd.'s share price and compare it with other companies in the industry.

Syngene International Ltd. Balance Sheet

Syngene International Ltd.'s balance sheet is a reflection of the company's financial health and stability. The company has a strong balance sheet with a healthy debt-to-equity ratio and a high current ratio. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools provide investors with a comprehensive understanding of the company's financial position and help them make informed investment decisions.

Syngene International Ltd. Annual Report

Syngene International Ltd.'s annual reports provide detailed information about the company's operations, financial performance, and future prospects. Investors can download the annual reports from Ticker and analyze the company's performance over the years. The annual report also includes information about the company's management team, corporate governance practices, and sustainability initiatives.

Syngene International Ltd. Dividend

Syngene International Ltd. has a consistent track record of paying dividends to its shareholders. The company has a dividend payout ratio of over 50%, which indicates that it is committed to sharing its profits with its shareholders. Investors can track Syngene International Ltd.'s dividend history using our pre-built screening tools and compare it with other companies in the industry.

Syngene International Ltd. Quarterly Result

Syngene International Ltd.'s quarterly results provide an insight into the company's performance over a shorter period. The company's revenue and profits can be affected by various factors such as changes in government policies, fluctuations in commodity prices, and global economic conditions. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools provide investors with a comprehensive understanding of the company's financial position and help them make informed investment decisions.

Syngene International Ltd. Stock Price

Syngene International Ltd.'s stock price is influenced by various factors such as the company's financial performance, market conditions, and investor sentiment. Investors can track Syngene International Ltd.'s stock price using our pre-built screening tools and compare it with other companies in the industry. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Syngene International Ltd. Price Chart

Syngene International Ltd.'s price chart provides a visual representation of the company's stock performance over a period of time. Investors can use our pre-built screening tools to analyze Syngene International Ltd.'s price chart and compare it with other companies in the industry. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Syngene International Ltd. News

Syngene International Ltd.'s news section provides investors with the latest updates about the company's operations, financial performance, and future prospects. Investors can stay informed about the company's developments by regularly checking the news section on Ticker.

Syngene International Ltd. Concall Transcripts

Syngene International Ltd.'s concall transcripts provide investors with an opportunity to listen to the management team's views on the company's performance and future prospects. Investors can download the concall transcripts from Ticker and gain valuable insights into the company's operations.

Syngene International Ltd. Investor Presentations

Syngene International Ltd.'s investor presentations provide a comprehensive overview of the company's operations, financial performance, and future prospects. Investors can download the investor presentations from Ticker and gain a deeper understanding of the company's business model and growth prospects.

Syngene International Ltd. Promoters

Syngene International Ltd.'s promoters include Biocon, a leading biotechnology company in India. The company has a strong backing from its promoters, which provides investors with a sense of security and stability.

Syngene International Ltd. Shareholders

Syngene International Ltd.'s shareholders include retail investors, institutional investors, and the company's promoters. The company has a diverse shareholder base, which indicates that it is a popular investment choice among investors.

Syngene International Ltd. ROCE

The Return on Capital Employed (ROCE) is an important financial ratio that assesses a company's efficiency in generating profits from its capital investments. Using the formula (EBIT/Capital Employed) * 100, ROCE measures the profitability of a company's underlying business operations relative to the capital employed. In the case of Syngene International Ltd., the ROCE ratio provides valuable insights into the company's ability to generate substantial returns from its capital investments. To access the ROCE data for Syngene International Ltd., please refer to the financials table or ratio section provided on this page.

Syngene International Ltd. EBITDA

EBITDA, an acronym for Earnings Before Interest, Taxes, Depreciation, and Amortization, is a crucial measure of a company's operational profitability. It gives an indication of the company's ability to generate revenue from its core operations without taking into account tax expenses, financing costs, or non-cash expenses. By examining Syngene International Ltd.'s EBITDA, investors can gain an understanding of the company's operational efficiency and its ability to generate earnings from its business activities. For the EBITDA data for Syngene International Ltd., please refer to the financials table or ratio section available on this page.

Syngene International Ltd. DPS

Dividends per Share (DPS) is a financial ratio that represents the amount of cash a company distributes to shareholders in the form of dividends for each outstanding share of stock. By analyzing the DPS figure, investors gain insights into the company's dividend policy and its commitment to returning value to its shareholders. Syngene International Ltd.'s DPS provides information on the company's dividend track record and its willingness to distribute profits to its shareholders. To access the DPS data for Syngene International Ltd., please refer to the financials table or ratio section provided on this page.

Syngene International Ltd. EPS

Earnings per Share (EPS) is a key financial ratio that measures the portion of a company's profit allocated to each outstanding share of common stock. By analyzing Syngene International Ltd.'s EPS figure, investors can gain valuable insights into the company's profitability and its ability to generate and retain earnings. EPS is an important metric that impacts the valuation of a company's stock and can help investors make informed decisions about investing in or divesting from a particular company. To access the EPS data for Syngene International Ltd., please refer to the financials table or ratio section available on this page.

Read More
X